The chemotherapy of onchocerciasis. XIV. Studies with mebendazole citrate.
Twenty patients from an area of vector control in the savannah region of northern Ghana with moderate to heavy infection with Onchocerca volvulus were randomised to receive two priming doses of levamisole 150 mg on two occasions followed either by mebendazole-citrate (500 mg) given daily or twice daily for 14 days. The two dose levels produced a similar effect on skin microfilariae (80-88% reduction) with a very mild systemic clinical reaction: low levels were maintained over 42 weeks. Both regimes were embryotoxic for O. volvulus; an effect which was transient in the single dose group but persisted for more than three months in the twice daily dose group. Mebendazole-citrate appeared to be absorbed more predictably than has been observed previously for mebendazole. The degree of systemic exposure as determined by measurement of AUC (0-24 h) was 2.5 times greater for the twice daily dose as compared to the single dose and this fact was reflected in the efficacy of the two dose regimes against the adult female worms at three months.
Awadzi
K
K
Onchocerciasis Chemotherapeutic Research Centre, Hohoe Hospital, Ghana.
Schulz-Key
H
H
Edwards
G
G
Breckenridge
A
A
Orme
M
M
Gilles
H
H
D000328:Adult; D000818:Animals; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D008463:Mebendazole / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D008842:Microfilariae / Q000187:drug effects; D008875:Middle Aged; D009854:Onchocerca / Q000187:drug effects; D009855:Onchocerciasis / Q000188:drug therapy*
D007978:Levamisole; D008463:Mebendazole